![]() |
Name |
Eutyscoparol C
|
Molecular Formula | C15H20O3 | |
IUPAC Name* |
2-[(E)-hept-1-enyl]-6-hydroxy-3-methoxybenzaldehyde
|
|
SMILES |
CCCCC/C=C/C1=C(C=CC(=C1C=O)O)OC
|
|
InChI |
InChI=1S/C15H20O3/c1-3-4-5-6-7-8-12-13(11-16)14(17)9-10-15(12)18-2/h7-11,17H,3-6H2,1-2H3/b8-7+
|
|
InChIKey |
CEVWXYPMUHMOQN-BQYQJAHWSA-N
|
|
Synonyms |
Eutyscoparol C
|
|
CAS | NA | |
PubChem CID | 156582447 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 248.32 | ALogp: | 4.6 |
HBD: | 1 | HBA: | 3 |
Rotatable Bonds: | 7 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 46.5 | Aromatic Rings: | 1 |
Heavy Atoms: | 18 | QED Weighted: | 0.571 |
Caco-2 Permeability: | -4.524 | MDCK Permeability: | 0.00002590 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.007 |
Human Intestinal Absorption (HIA): | 0.016 | 20% Bioavailability (F20%): | 0.009 |
30% Bioavailability (F30%): | 0.426 |
Blood-Brain-Barrier Penetration (BBB): | 0.586 | Plasma Protein Binding (PPB): | 96.82% |
Volume Distribution (VD): | 2.701 | Fu: | 3.17% |
CYP1A2-inhibitor: | 0.979 | CYP1A2-substrate: | 0.828 |
CYP2C19-inhibitor: | 0.92 | CYP2C19-substrate: | 0.499 |
CYP2C9-inhibitor: | 0.733 | CYP2C9-substrate: | 0.942 |
CYP2D6-inhibitor: | 0.514 | CYP2D6-substrate: | 0.862 |
CYP3A4-inhibitor: | 0.602 | CYP3A4-substrate: | 0.139 |
Clearance (CL): | 8.92 | Half-life (T1/2): | 0.691 |
hERG Blockers: | 0.011 | Human Hepatotoxicity (H-HT): | 0.009 |
Drug-inuced Liver Injury (DILI): | 0.045 | AMES Toxicity: | 0.451 |
Rat Oral Acute Toxicity: | 0.027 | Maximum Recommended Daily Dose: | 0.037 |
Skin Sensitization: | 0.932 | Carcinogencity: | 0.899 |
Eye Corrosion: | 0.681 | Eye Irritation: | 0.968 |
Respiratory Toxicity: | 0.888 |